A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR (Epidermal Growth Factor Receptor Activating) Mutation

Trial Profile

A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR (Epidermal Growth Factor Receptor Activating) Mutation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ADJUVANT
  • Most Recent Events

    • 12 Nov 2017 Primary endpoint (Disease free survival) has been met, according to the results published in the Lancet Oncology.
    • 12 Nov 2017 Results (Data cut-off: March 9, 2017) published in the Lancet Oncology
    • 18 Oct 2017 Results (cut-off date: 9 Mar 2017) assessing the main treatment failure pattern, presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top